

BLA 761071/S-024

SUPPLEMENT APPROVAL

Sandoz Inc.
Attention: Anthony Narisetty
Senior Manager, Regulatory Affairs, Biosimilars
100 College Road West
Princeton, NJ 08540

Dear Anthony Narisetty:

Please refer to your supplemental biologics license application (sBLA) received August 29, 2024, and your amendments, submitted under section 351(k) of the Public Health Service Act for Hyrimoz (adalimumab-adaz) injection.

This Prior Approval supplemental biologics application provides for:

- Hyrimoz (adalimumab-adaz) 40 mg/0.4 mL injection for subcutaneous use in a prefilled pen as interchangeable with US-Humira (adalimumab) 40 mg/0.4 mL injection for subcutaneous use in a prefilled pen,
- Hyrimoz (adalimumab-adaz) 40 mg/0.8 mL injection for subcutaneous use in a prefilled pen as interchangeable with US-Humira (adalimumab) 40 mg/0.8 mL injection for subcutaneous use in a prefilled pen, and
- Hyrimoz (adalimumab-adaz) 80 mg/0.8 mL injection for subcutaneous use in a prefilled pen as interchangeable with US-Humira (adalimumab) 80 mg/0.8 mL injection for subcutaneous use in a prefilled pen.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effectuated” (CBE) supplements.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effectuated” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

At this time, we have determined that no pediatric studies will be required under PREA for this sBLA.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR Part 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

If you have any questions, contact Tiffany Pfundt, PharmD, Regulatory Project Manager, at tiffany.pfundt@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Raj Nair, MD
Division Director
Division of Rheumatology and Transplant
Medicine
Office of Immunology and Inflammation
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

RAJ NAIR
07/29/2025 02:27:21 PM